Physician profile
Carlos E Maas
NPI 1710957907
$11,598.11
in general payments reported to CMS, 2019-2025
44 companies · $30.08 in 2025
The $30.08 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,185 · 2020: $1,031 · 2021: $1,575 · 2022: $2,071 · 2023: $2,507 · 2024: $2,199 · 2025: $30.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,617 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,617.11 |
| Education | $119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,027.41 | 2019-2024 | Breztri, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,874.61 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $1,322.92 | 2021-2025 | Glassia, Cuvitru |
| Actelion Pharmaceuticals US, INC. | $1,148.14 | 2019-2024 | Opsumit, Uptravi |
| Insmed, INC. | $697.92 | 2019-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $688.18 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $371.55 | 2019-2024 | Prolastin-C Liquid |
| Paratek Pharmaceuticals, INC. | $314.03 | 2019-2024 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $263.87 | 2019-2020 | |
| United Therapeutics Corporation | $243.86 | 2019-2024 | Tyvaso |
| Mylan Specialty L.P. | $229.59 | 2019-2024 | Yupelri |
| Genzyme Corporation | $202.47 | 2019-2024 | |
| Harmony Biosciences LLC | $197.35 | 2020-2023 | Wakix |
| Bayer Healthcare Pharmaceuticals INC. | $175.68 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $167.96 | 2019-2024 | Dupixent |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $155.33 | 2019-2021 | |
| Ethicon INC. | $132.29 | 2019-2020 | |
| Gilead Sciences, INC. | $123.29 | 2019-2022 | |
| Genentech USA, INC. | $115.98 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $109.55 | 2019 | |
| Csl Behring | $107.25 | 2022-2024 | Kcentra |
| Novartis Pharmaceuticals Corporation | $90.46 | 2019-2023 | |
| Electromed, INC. | $70.75 | 2022-2024 | Smartvest |
| Advanced Respiratory, INC | $67.52 | 2021 | |
| Shire North American Group INC | $66.93 | 2019 | |
| Ani Pharmaceuticals, INC. | $60.61 | 2023-2024 | Purified Cortrophin Gel |
| Baxter Healthcare | $59.53 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $56.67 | 2023-2024 | Recarbrio, Zerbaxa, Dificid |
| Vapotherm INC | $52.64 | 2019-2022 | |
| Resmed Corp | $49.28 | 2022-2024 | |
| Circassia INC. | $42.60 | 2019-2020 | |
| Boston Scientific Corporation | $41.92 | 2019-2021 | |
| Pulmonx Corporation | $41.27 | 2022-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Amgen INC. | $37.10 | 2022-2023 | Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $28.67 | 2024 | Lumryz |
| Axsome Therapeutics, INC. | $23.78 | 2023 | Sunosi |
| Apria Healthcare LLC | $21.25 | 2021 | |
| Pfizer INC. | $20.51 | 2024 | |
| Ambu INC. | $18.89 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2022 | |
| Olympus America INC. | $17.57 | 2021 | |
| Optinose US, INC. | $15.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.92 | 2021 | |
| Breas Medical, INC. | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Maas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.